Back to Search Start Over

Evaluation of Commercially Available High-Throughput SARS-CoV-2 Serologic Assays for Serosurveillance and Related Applications

Authors :
Mars Stone
Eduard Grebe
Hasan Sulaeman
Clara Di Germanio
Honey Dave
Kathleen Kelly
Brad J. Biggerstaff
Bridgit O. Crews
Nam Tran
Keith R. Jerome
Thomas N. Denny
Boris Hogema
Mark Destree
Jefferson M. Jones
Natalie Thornburg
Graham Simmons
Mel Krajden
Steve Kleinman
Larry J. Dumont
Michael P. Busch
Source :
Emerging Infectious Diseases, vol 28, iss 3
Publication Year :
2022
Publisher :
Centers for Disease Control and Prevention (CDC), 2022.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serosurveys can estimate cumulative incidence for monitoring epidemics, requiring assessment of serologic assays to inform testing algorithm development and interpretation of results. We conducted a multilaboratory evaluation of 21 commercial high-throughput SARS-CoV-2 serologic assays using blinded panels of 1,000 highly characterized specimens. Assays demonstrated a range of sensitivities (96%-63%), specificities (99%-96%), and precision (intraclass correlation coefficient 0.55-0.99). Durability of antibody detection was dependent on antigen and immunoglobulin targets; antispike and total Ig assays demonstrated more stable longitudinal reactivity than antinucleocapsid and IgG assays. Assays with high sensitivity, specificity, and durable antibody detection are ideal for serosurveillance, but assays demonstrating waning reactivity are appropriate for other applications, including correlation with neutralizing activity and detection of anamnestic boosting by reinfections. Assay performance must be evaluated in context of intended use, particularly in the context of widespread vaccination and circulation of SARS-CoV-2 variants.

Details

ISSN :
10806059 and 10806040
Volume :
28
Database :
OpenAIRE
Journal :
Emerging Infectious Diseases
Accession number :
edsair.doi.dedup.....19ea727991434e9125b45ef63d60dc9e